Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B.
Sommer A, et al. Among authors: harrenga a.
Cancer Res. 2016 Nov 1;76(21):6331-6339. doi: 10.1158/0008-5472.CAN-16-0180. Epub 2016 Aug 19.
Cancer Res. 2016.
PMID: 27543601